Holen Sie sich die Stockscreener-App
6.22
2.81%
0.17
Handel nachbörslich:
6.23
0.01
+0.16%
Schlusskurs vom Vortag:
$6.05
Offen:
$6.03
24-Stunden-Volumen:
3.46M
Relative Volume:
0.70
Marktkapitalisierung:
$1.92B
Einnahmen:
$493.67M
Nettoeinkommen (Verlust:
$-104.69M
KGV:
-18.29
EPS:
-0.34
Netto-Cashflow:
$-31.51M
1W Leistung:
+5.25%
1M Leistung:
+10.28%
6M Leistung:
-34.80%
1J Leistung:
-39.49%
1-Tages-Spanne:
$6.025
$6.225
1-Wochen-Bereich:
$5.915
$6.77
52-Wochen-Spanne:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Vergleichen Sie FOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.22 | 1.82B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
What drives Amicus Therapeutics Inc. stock priceFree Stock Market Knowledge Sharing - Autocar Professional
What analysts say about Amicus Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com
Published on: 2025-07-23 00:04:03 - jammulinksnews.com
Amicus Therapeutics Inc. Stock Analysis and ForecastHigh-profit capital plays - printweek.in
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewswire
Amicus Therapeutics Sets Date for Q2 Earnings: Key Updates Expected from Rare Disease Pipeline - Stock Titan
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Upgraded by Morgan Stanley - MarketBeat
Is Amicus Therapeutics Inc. a good long term investmentRemarkable growth - PrintWeekIndia
58,396 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Purchased by Edgestream Partners L.P. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpWhat's Next? - MarketBeat
Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda - MSN
Amicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switching - MSN
Amicus stock gains as Morgan Stanley upgrades (FOLD:NASDAQ) - Seeking Alpha
Amicus Therapeutics: A Biotech Buy with Legal, Product, and Market Catalysts - AInvest
Amicus Therapeutics (FOLD) Soars 10.05% on Japan Approval - AInvest
Rice Hall James & Associates LLC Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics stock upgraded to Overweight by Morgan Stanley on IP strength - Investing.com Canada
Stephens Investment Management Group LLC Makes New $5 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
10 Best Small-Cap Stocks to Buy According to Billionaires - Insider Monkey
Q2 EPS Estimate for Amicus Therapeutics Increased by Analyst - MarketBeat
Zacks Research Issues Optimistic Forecast for FOLD Earnings - MarketBeat
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $16.22 - MarketBeat
Amicus Therapeutics (FOLD): Securing Rare Disease Dominance Through Strategic Deals and Pipeline Momentum - AInvest
TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT - Yahoo Finance
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm - Longview News-Journal
Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan’s Ministry of Health, Labour and Welfare (MHLW) - MSN
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):